Biomedical Engineering Reference
In-Depth Information
71. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, et al.
Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003; 13:
2419-2422.
72. Jazrawi E, Cosio BG, Barnes PJ, Adcock IM. Inhibition of IKK2 and JNK
differentially regulates GM-CSF and IL-8 release in epithelial cells and alveo-
lar macrophages. Am J Respir Crit Care Med 2003; 167:A798.
73. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R. Differential IKK
activation and I
k
B
a
degradation by interleukin-1
b
and tumor necrosis factor-
a in human U937 monocytic cells: evidence for additional regulatory steps in
KB-dependent transcription. J Biol Chem 1999; 274:19965-19972.
74. Catley MC, Cambridge LM, Nasuhara Y, Ito K, Chivers JE, Beaton A, et al.
Inhibitors of protein kinase C prevent activated transcription: role of events
downstream of NF-
k
B DNA binding. J Biol Chem 2004; 279:18457-18466.
75. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways
mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298:
1911-1912.
76. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as
therapeutic targets for inflammatory diseases.
77. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhi-
bition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology
2000; 47:185-201.
78. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC,
et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory
cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol
2000; 279:L895-L902.
79. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira dSA, Stanford WL, Bolon B, et al.
Function of PI3K
g
in thymocyte development, T cell activation, and neutro-
phil migration. Science 2000; 287:1040-1046.
80. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of
phosphoinositide 3-kinase inhibitors. Chem Biol 2003; 10:207-213.
81. Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferator-activated recep-
tors and the control of inflammation. Curr Drug Targets Inflamm Allergy
2002; 1:243-248.
82. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation
of peroxisome proliferator-activated receptors in human airway smooth mus-
cle cells has a superior anti-inflammatory profile to corticosteroids: relevance
for chronic obstructive pulmonary disease therapy. J Immunol 2003; 170:
2663-2669.
83. Harris SG, Phipps RP. Induction of apoptosis in mouse T cells upon peroxi-
some proliferator-activated receptor gamma (PPAR-
g
) binding. Adv Exp Med
Biol 2002; 507:421-425.
84. Davenpeck KL, Berens KL, Dixon RA, Dupre B, Bochner BS. Inhibition of
adhesion of human neutrophils and eosinophils to P-selectin by the sialyl
Lewis antagonist TBCI269: preferential activity against neutrophil adhesion
in vitro. J Allergy Clin Immunol 2000; 105:769-775.
85. Noguera A, Busquets X, Sauleda J, Villaverde JM, Macnee W, Agusti AG.
Expression of adhesion molecules and G proteins in circulating neutrophils
